To derive MYCN amplification-specific signatures, we compared stage 4- and 4+ tumor, and detected 4602 probesets within 1501 genes that may undergo splicing disruption, and 2318 transcript clusters with expression changes during MYCN status change. This evidence concerns the gene MYCN and neoplasm.